APPENDIX B.
External validation
| Studies | GFR Measurement Method | Race/ethnic group N (%) |
|||
|---|---|---|---|---|---|
| White and other | Black | Native American and Hispanic | Asian | ||
| CKD-EPI Validation Dataset | |||||
| Baylor 34 | Iothalamate | 651 (19) | 47 (10) | 3 (2) | 7 (1) |
| CCF P CKD | Iothalamate | 92 (3) | 9 (2) | 1 (0.5) | 1 (0.1) |
| CCF P donors | Iothalamate | 83 (2) | 10 (2) | 2 (1) | 1 (0.1) |
| CRIC 31 | Iothalamate | 156 (5) | 127 (26) | 3 (2) | 12 (1) |
| CRISP 35 | Iothalamate | 172 (5) | 21 (4) | 3 (2) | 2 (0.2) |
| DNA donor | Iothalamate | 60 (2) | 19 (4) | 28 (15) | 2 (0.2) |
| DNA Tx | Iothalamate | 116 (3) | 61 (13) | 27 (15) | 5 (0.5) |
| DRDS 29 | Iothalamate | 0 (0) | 0 (0) | 118 (64) | 0 (0) |
| Groningen 36 | Iothalamate | 418 (12) | 4 (1) | 0 (0) | 0 (0) |
| Groningen donors 37 | Iothalamate | 43 (1) | 0 (0) | 0 (0) | 0 (0) |
| Lund 38 | Iohexol | 387 (11) | 0 (0) | 0 (0) | 0 (0) |
| Lund donors 38 | Iohexol | 7 (0.2) | 0 (0) | 0 (0) | 0 (0) |
| NephroTest CKD 39 | EDTA | 371 (11) | 37 (8) | 30 (3) | 0 (0) |
| NephroTest donors 39 | EDTA | 332 (10) | 43 (9) | 7 (1) | 0 (0) |
| RASS Study 40 | Iothalamate, Iohexol | 245 (7) | 6 (1) | 0 (0) | 0 (0) |
| Steno Diabetes Center 41-45 | EDTA | 245 (7) | 0 (0) | 0 (0) | 0 (0) |
| Non-US and Europe Validation Dataset | |||||
| China | DTPA | 0 (0) | 0 (0) | 675 (68) | 0 (0) |
| Japan | Inulin | 0 (0) | 0 (0) | 248 (25) | 0 (0) |
| South Africa | EDTA | 0 (0) | 99 (21) | 0 (0) | 0 (0) |
Abbreviations: CCF P, Cleveland Clinic Foundation Prospective; CKD, Chronic Kidney Disease; CRIC, Chronic Renal Insufficiency Cohort; CRISP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease; DNA, Dallas Nephrology Associates; DRDS, Diabetic Renal Disease Study; RASS, Renin Angiotensin System Study.